Fol. Biol. 2011, 57, 191-199

https://doi.org/10.14712/fb2011057050191

Study of the Effect of Neoadjuvant Chemotherapy on the Status of Her2/neu

H. Skálová1, P. Dundr1, C. Povýšil1, Z. Velenská1, L. Petruželka2, Daniel Tvrdík1

1Institute of Pathology, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Prague, Czech Republic
2Department of Oncology, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Prague, Czech Republic

Received April 2011
Accepted June 2011

References

1. Adams, A. L., Eltoum, I., Krontiras, H., Wang, W., Chhieng, D. C. (2008) The effect of neoadjuvant chemotherapy on histologic grade, hormone receptor status, and Her2/neu status in breast carcinoma. Breast J. 14, 141-146. <https://doi.org/10.1111/j.1524-4741.2007.00544.x>
2. Andrulis, I. L., Bull, S. B., Blackstein, M. E., Sutherland, D., Mak, C., Sidlofsky, S., Pritzker, K. P., Hartwick, R. W., Hanna, W., Lickley, L., Wilkinson, R., Qizilbash, A., Ambus, U., Lipa, M., Weizel, H., Katz, A., Baida, M., Mariz, S., Stoik, G., Dacamara, P., Strongitham, D., Geddie, W., McCready, D. (1998) Neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group. J. Clin. Oncol. 16, 1340-1349. <https://doi.org/10.1200/JCO.1998.16.4.1340>
3. Biéche, I., Onody, P., Laurendeau, I., Martine, O., Vidaud, D., Lidereau, R., Vidaud, M. (1999) Real-time reverse transcription-PCR assay for future management of ERBB2based clinical applications. Clin. Chem. 45, 1148-1156. <https://doi.org/10.1093/clinchem/45.8.1148>
4. D’Alfonso, T., Liu, Y. F., Monni, S., Rosen, P. P., Shin, S. J. (2010) Accurately assessing Her2/neu status in needle core biopsy of breast cancer patients in the era of neoadjuvant therapy: emerging questions and considerations addressed. Am. J. Surg. Pathol. 34, 575-581. <https://doi.org/10.1097/PAS.0b013e3181d65639>
5. Davoli, A., Hocevar, B. A., Brown, T. L. (2010) Progression and treatment of HER2-positive breast cancer. Cancer Chemother. Pharmacol. 65, 611-623. <https://doi.org/10.1007/s00280-009-1208-1>
6. Duffy, M. J. (2005) Predictive markers in breast and other cancers: a review. Clin. Chem. 51, 494-503. <https://doi.org/10.1373/clinchem.2004.046227>
7. Early Breast Cancer Trialists’ Collaborative Group (1998) Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 352, 930-942.
8. Hoff, E. R., Tubb, R. R., Myles, J. L., Procop, G. W. (2002) Her2/neu amplification in breast cancer: stratification by tumor type and grade. Am. J. Clin. Pathol. 117, 916-921. <https://doi.org/10.1309/4NTU-N6K4-F8JF-EWRX>
9. Lee, H., Lee, J., Park, I. A. (2007) Changes in protein expression in breast cancer after anthracycline-based chemotherapy. Korean J. Pathol. 41, 165-170.
10. Lyon, E., Millson, A., Lowery, M. C., Woods, R., Wittwer, C. T. (2001) Quantification of HER2/neu gene amplification by competitive PCR using fluorescent melting curve analysis. Clin. Chem. 47, 844-851. <https://doi.org/10.1093/clinchem/47.5.844>
11. Pandis, N., Bardi, G., Jin, Y., Dietrich, C., Johansson, B., Andersen, J., Mandahl, N., Mitelman, F., Heim, S. (1994) Unbalanced t(1;16) as the sole karyotypic abnormality in a breast carcinoma and its lymph node metastasis. Cancer Genet. Cytogenet. 75, 158-159. <https://doi.org/10.1016/0165-4608(94)90172-4>
12. Pandis, N., Jin, Y., Gorunova, L., Petersson, C., Bardi, G., Idvall, I., Johansson, B., Ingvar, C., Mandahl, N., Mitelman, F. (1995a) Chromosome analysis of 97 primary breast carcinomas: Identification of eight karyotypic subgroups. Genes Chromosomes Cancer 12, 173-185. <https://doi.org/10.1002/gcc.2870120304>
13. Pandis, N., Teixeira, M. R., Gerdes, A. M., Limon, J., Bardi, G., Anderson, J. A., Idvall, I., Mandahl, N., Mitelman, F., Heim, S. (1995b) Chromosome abnormalities in bilateral breast carcinomas. Cancer 76, 250-258. <https://doi.org/10.1002/1097-0142(19950715)76:2<250::AID-CNCR2820760215>3.0.CO;2-W>
14. Pandis, N., Teixeira, M. R., Adeyinka, A., Rizou, H., Bardi, G., Mertens, F., Andersen, J. A., Bondeson, L., Sfikas, K., Qvist, H., Apostolikas, N., Mitelman, F., Heim, S. (1998) Cytogenetic comparison of primary tumors and lymph node metastases in breast cancer patients. Genes Chromosomes Cancer 22, 122-129. <https://doi.org/10.1002/(SICI)1098-2264(199806)22:2<122::AID-GCC6>3.0.CO;2-Z>
15. Paterson, M. C., Dietrich, K. D., Danyluk, J., Paterson, A. H., Lees, A. W., Jamil, N., Hanson, J., Jenkins, H., Krause, B. E., McBlain, W. A. (1991) Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer. Cancer Res. 51, 556-567.
16. Press, M. F., Bernstein, L., Thomas, P. A., Meisner, L. F., Zhou, J. Y., Ma, Y., Hung, G.., Robinson, R. A., Harris, C., El-Naggar, A., Slamon, D. J., Phillips, R. N., Ross, J. S., Wolman, S. R., Flom, K. J. (1997) HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J. Clin. Oncol. 15, 2894-2904. <https://doi.org/10.1200/JCO.1997.15.8.2894>
17. Quddus, R. M., Sung, J. C., Zhang, C., Pasqueriello, T., Eklund, M., Steinhoff, M. M. (2005) Her2/neu expression in locally advanced breast carcinomas: preand post-neoadjuvant chemotherapy. Breast Cancer 12, 294-298. <https://doi.org/10.2325/jbcs.12.294>
18. Riehle, U., Mader, A., Brandstetter, T., Rühe, J., Zur Hausen, A., Stickeler, E. (2010) Nucleic acid sequence-based amplification in formalin-fixed and paraffin-embedded breastcancer tissues. J. Clin. Pathol. 63, 1071-1076. <https://doi.org/10.1136/jcp.2010.078766>
19. Ro, J. S., El-Naggar, A., Ro, J. Y., Blick, M., Frye, D., Fraschini, G.., Fritsche, H., Hortobagyi, G.. (1989) C-erbB-2 amplification in node-negative human breast cancer. Cancer Res. 49, 6941-6944.
20. Saint-Ruf, C., Gerbault-Seureau, M., Viegas-Péquignot, E., Zafrani, B., Cassingena, R., Dutrillaux, B. (1990) Protooncogene amplification and homogeneously staining regions in human breast carcinomas. Genes Chromosomes Cancer 2, 18-26. <https://doi.org/10.1002/gcc.2870020105>
21. Saint-Ruf, C., Gerbault-Sanreau, M., Viegas-Péquignot, E., Zafrani, B., Malfoy, B., Dutrillaux, B. (1991) Recurrent homogeneously staining regions in 8pl in breast cancer and lack of amplification of POLB, LHRH, and PLAT genes. Cancer Genet. Cytogenet. 52, 27-35. <https://doi.org/10.1016/0165-4608(91)90050-5>
22. Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., McGuire, W. L. (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science 235, 177-182. <https://doi.org/10.1126/science.3798106>
23. Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G.., Udova, J., Ullrich, A. (1989) Studies of Her2/neu proto-oncogene in human breast and ovarian cancer. Science 244, 707-712. <https://doi.org/10.1126/science.2470152>
24. Taucher, S., Rudas, M., Mader, R. M., Gnant, M., Sporn, E., Dubsky, P., Roka, S., Bachleitner, T., Fitzal, F., Kandioler, D., Wenzel, C., Steger, G.. G., Mittlböck, M., Jakesz, R. (2003) Influence of neoadjuvant therapy with epirubicin and docetaxel on the expression of Her2/neu in patients with breast cancer. Breast Cancer Res. Treat. 82, 207-213. <https://doi.org/10.1023/B:BREA.0000004378.15859.51>
25. Tavassoli, F. A., Devilee, P. (2004) WHO Classification of Tumours. Pathology and Genetics. Tumours of the Breast and Female Genital Organs. IARC Press, Lyon.
26. Teixeira, M. R., Pandis, N., Bardi, G., Andersen, J. A., Mandhal, N., Mitelman, F., Heim, S. (1994) Cytogenetic analysis of multifocal breast carcinomas: Detection of karyotypically unrelated clones as well as clonal similarities between tumour foci. Br. J. Cancer 70, 922-927. <https://doi.org/10.1038/bjc.1994.421>
27. Teixeira, M. R., Tsarouha, H., Kraggerud, S. M., Pandis, N., Dimitriadis, E., Andersen, J. A., Lothe, R. A., Heim, S. (2001) Evaluation of breast cancer polyclonality by combined chromosome banding and comparative genomic hybridization analysis. Neoplasia 3, 204-214. <https://doi.org/10.1038/sj.neo.7900152>
28. Tinari, N., Lattanzio, R., Natoli, C., Cianchetti, E., Angelucci, D., Ricevuto,E., Ficorella C., Marchetti, P., Alberti, S., Piantelli, M., Iacobelli, S. (2006) Changes of topoisomerase IIα expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival. Clin. Cancer Res. 12, 1501-1506. <https://doi.org/10.1158/1078-0432.CCR-05-0978>
29. Tvrdík, D., Svatošová, J., Dundr, P., Povýšil, C. (2005) Molecular diagnosis of synovial sarcoma: detection of SYT-SSX1/2 fusion transcripts by RT-PCR in paraffin-embedded tissue. Med. Sci. Monit. 11, MT1-7.
30. Van de Vijver, M. (2005) Gene-expression profiling and the future of adjuvant therapy. Oncologist 10 (Suppl 2), 30-34. <https://doi.org/10.1634/theoncologist.10-90002-30>
31. Varga, Z., Caduff, R., Pestalozzi, B. (2005) Stability of the Her2 gene after primary chemotherapy in advanced breast cancer. Virchows Arch. 446, 136-141. <https://doi.org/10.1007/s00428-004-1164-4>
front cover

ISSN 0015-5500 (Print) ISSN 2533-7602 (Online)

Open access journal

Submissions

Archive